News coverage about Zealand Pharma A/S (NASDAQ:ZEAL) has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zealand Pharma A/S earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.4349188322723 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Zealand Pharma A/S (ZEAL) opened at 18.70 on Monday. The company’s market capitalization is $575.01 million. The firm has a 50 day moving average price of $19.04 and a 200 day moving average price of $18.66. Zealand Pharma A/S has a one year low of $16.07 and a one year high of $20.37.

Several equities analysts have recently issued reports on ZEAL shares. Goldman Sachs Group, Inc. (The) started coverage on Zealand Pharma A/S in a research note on Wednesday, September 27th. They set a “buy” rating on the stock. Needham & Company LLC started coverage on Zealand Pharma A/S in a report on Tuesday, September 5th. They issued a “buy” rating and a $26.00 price objective for the company. Guggenheim started coverage on Zealand Pharma A/S in a report on Tuesday, September 5th. They issued a “buy” rating and a $28.00 price objective for the company. Finally, Morgan Stanley started coverage on Zealand Pharma A/S in a report on Tuesday, September 5th. They issued an “overweight” rating and a $28.00 price objective for the company.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/09/zealand-pharma-as-zeal-given-coverage-optimism-rating-of-0-08.html.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Receive News & Stock Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related stocks with our FREE daily email newsletter.